Oneness Biotech : The findings of the MoA studies on Fespixon(ON101) under collaboration with TMU and NYCU have been accepted and published by a renown SCI journal, JID Innovations
The findings of the MoA studies on Fespixon(ON101)
under collaboration with TMU and NYCU have been accepted
and published by a renown SCI journal, JID Innovations
Date of events
2022/06/02
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/06/02
2.Company name:ONENESS BIOTECH CO., LTD.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:
Fespixon (research code: ON101) is the first-in-class macrophage-regulation
new drug which demonstrated clinical superiority in the healing of the
diabetic foot ulcers. The in vitro and in vivo data confirmed that Fespixon
promotes the healing by decreasing the pro-inflammatory M1 macrophages and
increasing the pro-regenerative M2a/M2c macrophages via stimulating
adipose-derived progenitor cells to secrete GCSF and CXCL3. The study
findings have been submitted to and published by JID Innovations, the open
access of JID, a leading dermatological journal.
6.Countermeasures:None
7.Any other matters that need to be specified:
(1)Two global leading dermatological medical associations, Society for
Investigative Dermatology (SID) and European Society for Dermatological
Research (ESDR) have established the Journal of Investigative Dermatology
(JID) since 1938. JID has been the leading dermatological research
journal. The articles on JID is more basic-research-driven and in order
to accelerate more researches into treatment and application for medical
dermatology, SID and ESDR established JID Innovations, an open-access
journal in 2021. The manuscripts for researches into pathology of
dermatological disorders and therapeutic approaches will be peer-reviewed
by medical dermatologists and key opinion leaders for online publication.
JID innovations has not received an impact factor yet as it has not been
established for 2 years. However, many influential review articles were
already published on this journal. With the meticulous review process,
JID Innovations has become an important journal in medical dermatology
in Europe and the U.S.
(2)The mechanism of action of Fespixon has been reconfirmed by in vitro
and in vivo studies and published on JID Innovations. This is an
acknowledgement by the leading dermatological journal on Fespixon's
unique mechanism of action and its scientific evidence. The open access
will increase the understanding of the podiatric and dermatological
specialists on Fespixon's first-in-class mechanism in treating chronic
ulcers and also raise the global profile of the new drug. It is hoped
that this will benefit the global DFU patients.
(3)The article is available online on JID Innovations:
https://www.jidinnovations.org/article/S2667-0267(22)00046-7/fulltext
Attachments
Original Link
Original Document
Permalink
Disclaimer
Oneness Biotech Co Ltd. published this content on 02 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 June 2022 12:41:01 UTC.
ONENESS BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the research, development, production and sales of health products. The Company's main products include health supplies, health food and healthy food. The Company is also involved in the development of new drugs for the treatment of wound healing in chronic diabetic foot ulcers, as well as the development of new anticancer drugs. The Company distributes its products in domestic market.
Oneness Biotech : The findings of the MoA studies on Fespixon(ON101) under collaboration with TMU and NYCU have been accepted and published by a renown SCI journal, JID Innovations